A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.

Background: New influenza vaccines are needed to increase vaccine efficacy. Adjuvants may allow hemagglutinin (HA) dose-sparing with enhanced immunogenicity. MAS-1 is an investigational low viscosity, free-flowing, water-in-oil emulsion-based adjuvant/delivery system comprised of stable nanoglobular aqueous droplets.
Methods: A phase 1, double-blind, safety and immunogenicity, HA dose escalation, randomized clinical trial was conducted. MAS-1 adjuvant with 1, 3, 5 or 9 µg per HA derived from licensed seasonal trivalent high dose inactivated influenza vaccine (IIV, Fluzone HD 60 µg per HA) in a 0.3 mL dose were compared to standard dose IIV (Fluzone SD, 15 µg per HA). Safety was measured by reactogenicity, adverse events, and clinical laboratory tests. Serum hemagglutination inhibition (HAI) antibody titers were measured for immunogenicity.
Results: Seventy-two subjects, aged 18-47 years, received one dose of either 0.3 mL adjuvanted vaccine or SD IIV intramuscularly. Common injection site and systemic reactions post-vaccination were mild tenderness, induration, pain, headache, myalgia, malaise and fatigue. All reactions resolved within 14 days post-vaccination. Safety laboratory measures were not different between groups. Geometric mean antibody titers, geometric mean fold increases in antibody titer, seroconversion rates and seroprotection rates against vaccine strains were in general higher and of longer duration (day 85 and 169 visits) with MAS-1-adjuvanted IIV at all doses of HA compared with SD IIV. Adjuvanted vaccine induced higher antibody responses against a limited number of non-study vaccine influenza B and A/H3N2 viruses including ones from subsequent years.
Conclusion: MAS-1 adjuvant in a 0.3 mL dose volume provided HA dose-sparing effects without safety concerns and induced higher HAI antibody and seroconversion responses through at least 6 months, demonstrating potential to provide greater vaccine efficacy throughout an influenza season in younger adults. In summary, MAS-1 may provide enhanced, more durable and broader protective immunity compared with non-adjuvanted SD IIV. Clinical Trial Registry: ClinicalTrials.gov # NCT02500680.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Geoffrey J. Gorse and Sharon E. Frey report financial support, equipment, drugs, or supplies for the conduct of the study were provided to Saint Louis University by Nova Immunotherapeutics and Mercia Pharma, Inc. and statistical analysis (in large part done by EMMES Company, Inc). Jeanine May and Heather Hill report financial support was provided by Nova Immunotherapeutics and Mercia Pharma, Inc. to Emmes Company, LLC for study monitoring, data management, and data and statistical analyses. Helen Buck, Peter White, and Hussain Mulla report a relationship with Nova Immunotherapeutics that includes: employment. Peter Blackburn and Stephen Grimes report a relationship with Mercia Pharma, Inc. that includes: employment. Peter Blackburn and Peter White report a relationship with Mercia Pharma, Inc. that includes: equity or stocks. Peter White reports a relationship with Nova Immunotherapeutics that includes: equity or stocks. Peter Blackburn has patent pending that is Licensed to: Nova Immunotherapeutics and Assigned to: Mercia Pharma, Inc.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)